Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMNLY9R)

• Drug Name: YM-16151-4 Drug Info
• Synonyms: YM-151; YM-16151-1; (-)-YM-16151-1

Indication

Disease Entry	ICD 11	Status	REF
Hypertension	BA00-BA04	Phase 1	[1]

• Cross-matching ID:
  PubChem CID: 128387
  CAS Number: CAS 103434-30-6
  TTD Drug ID: DMNLY9R

Molecule-Related Drug Atlas

Drug(s) Targeting Adrenergic receptor beta-1 (ADRB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[2]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[3]
Norepinephrine	DMOUC09	Alopecia	ED70	Approved	[4]
Atenolol	DMNKG1Z	Angina pectoris	BA40	Approved	[5]
Acebutolol	DM0TI4U	Hypertension	BA00-BA04	Approved	[5]
Metoprolol	DMOJ0V6	Acute coronary syndrome	BA41	Approved	[5]
Timolol	DM3NXRU	High blood pressure	BA00	Approved	[6]
Isoproterenol	DMK7MEY	Atrioventricular block		Approved	[7]
Betaxolol	DM6EUL5	Hypertension	BA00-BA04	Approved	[8]
Sotalol	DML60TN	Sinus rhythm disorder	BC9Y	Approved	[9]

Drug(s) Targeting Calcium channel unspecific (CaC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nicardipine	DMCDYW7	High blood pressure	BA00	Approved	[10]
Clevidipine butyrate	DMW4M97	Hypertension	BA00-BA04	Approved	[11]
Nisoldipine	DM7ISKJ	Hypertension	BA00-BA04	Approved	[12]
Felodipine	DMOSW35	Hypertension	BA00-BA04	Approved	[13]
Nimodipine	DMQ0RKZ	Cerebral vasospasm	BA85.Z	Approved	[14]
Bepridil	DM0RKS4	Chronic/stable angina	BA40.1	Approved	[15]
Isradipine	DMA5XGH	Hypertension	BA00-BA04	Approved	[15]
DIPROTEVERINE HYDROCHLORIDE	DMG8U6M	Angina pectoris	BA40	Phase 3	[16]
ATI-2042	DMWP59B	Atrial fibrillation	BC81.3	Phase 2	[17]
HBI-3000	DM74ZKN	Heart arrhythmia	BC65	Phase 2	[18]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor beta-1 (ADRB1)	TTR6W5O	ADRB1_HUMAN	Modulator	[1]
Calcium channel unspecific (CaC)	TT5HONZ	NOUNIPROTAC	Modulator	[1]

References

• [1] Antianginal effects of YM-16151-4 in various experimental angina models. J Cardiovasc Pharmacol. 1993 May;21(5):701-8.
• [2] Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
• [3] Adrenergic activation of electrogenic K+ secretion in guinea pig distal colonic epithelium: involvement of beta1- and beta2-adrenergic receptors. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G269-77.
• [4] Impact of exogenous beta-adrenergic receptor stimulation on hepatosplanchnic oxygen kinetics and metabolic activity in septic shock. Crit Care Med. 1999 Feb;27(2):325-31.
• [5] Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6.
• [6] Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. Drugs Aging. 2006;23(12):977-95.
• [7] Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
• [8] beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signaling. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):519-29.
• [9] beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25.
• [10] Effect of intracoronary nicardipine on cardiac enzymes after elective percutaneous coronary intervention. Clin Cardiol. 2009 Jun;32(6):315-20.
• [11] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [12] RT-PCR and pharmacological analysis of L-and T-type calcium channels in rat carotid body. Adv Exp Med Biol. 2009;648:105-12.
• [13] Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs. J Pharmacol Exp Ther. 2009 Feb;328(2):621-7.
• [14] Influence of bupropion and calcium channel antagonists on the nicotine-induced memory-related response of mice in the elevated plus maze. Pharmacol Rep. 2009 Mar-Apr;61(2):236-44.
• [15] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [16] Prenatal toxicity studies in rats and rabbits with the calcium channel blocker diproteverine. Reprod Toxicol. 1996 Jan-Feb;10(1):43-9.
• [17] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [18] Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J Cardiovasc Pharmacol. 2011 Jan;57(1):79-85.